DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2008 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: ganciclovir

Summary for Generic Name: ganciclovir

Tradenames:5
Patents:1
Applicants:4
NDAs:5
Drug Master File Entries: see list20
Suppliers: see list1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Clinical Trials for: ganciclovir

Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis
Status: Recruiting Condition: Cytomegalovirus Anterior Segment Infection; Anterior Uveitis; Endotheliitis

A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy
Status: Completed Condition: Cytomegalovirus Retinitis; HIV Infections

Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
Status: Completed Condition: Cytomegalovirus Infection

Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure
Status: Recruiting Condition: Acute Lung Injury; Acute Respiratory Distress Syndrome; Respiratory Failure

Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
Status: Recruiting Condition: Infection in Solid Organ Transplant Recipients

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients
Status: Completed Condition: Colitis; HIV Infections

Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
Status: Terminated Condition: Allogeneic Stem Cell Transplantation

A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir
Status: Completed Condition: Cytomegalovirus Retinitis; HIV Infections

A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis
Status: Completed Condition: Cytomegalovirus Retinitis; HIV Infections

Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
Status: Not yet recruiting Condition: Conjunctivitis; Adenovirus.

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Patented / Exclusive Use
Bausch And Lomb
VITRASERT
ganciclovir
IMPLANT; IMPLANTATION020569Mar 4, 1996RXYes5,378,475<disabled>
Ranbaxy
GANCICLOVIR
ganciclovir
CAPSULE; ORAL076457Jun 27, 2003RXNo<disabled>
Ranbaxy
GANCICLOVIR
ganciclovir
CAPSULE; ORAL076457Jun 27, 2003RXYes<disabled>
Roche Palo
CYTOVENE
ganciclovir
CAPSULE; ORAL020460Dec 12, 1997DISCNNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc